8 assets in Chediak-Higashi Syndrome

Therapeutic assets addressing Chediak-Higashi Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Melphalan Chediak-Higashi Syndrome	Washington University School of Medicine	P2	B (63)
Alemtuzumab Chediak-Higashi Syndrome	Washington University School of Medicine	P2	B (62)
Fludarabine Chediak-Higashi Syndrome	Washington University School of Medicine	P2	B (62)
Thiotepa Chediak-Higashi Syndrome	Washington University School of Medicine	P2	CCC (53)
Busulfanum Chediak-Higashi Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Cyclophosphamide Chediak-Higashi Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Mesna Chediak-Higashi Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)
Nivestim Chediak-Higashi Syndrome	Masonic Cancer Center, University of Minnesota	N/A	D (30)